Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells

OBJECTIVE: To report 3 patients with relapsing-remitting multiple sclerosis (RRMS) showing vitiligo after treatment with alemtuzumab. METHODS: Retrospective case series including flow cytometric analyses and T-cell receptor (TCR) sequencing of peripheral blood mononuclear cells. RESULTS: We describe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neurology
Päätekijät: Ruck, Tobias, Pfeuffer, Steffen, Schulte-Mecklenbeck, Andreas, Gross, Catharina C., Lindner, Maren, Metze, Dieter, Ehrchen, Jan, Sondermann, Wiebke, Pul, Refik, Kleinschnitz, Christoph, Wiendl, Heinz, Meuth, Sven G., Klotz, Luisa
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lippincott Williams & Wilkins 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6329330/
https://ncbi.nlm.nih.gov/pubmed/30404783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000006648
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia